Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.71
$64.09
$131.98
$14.05B0.691.49 million shsN/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$23.96
-2.8%
$21.85
$2.10
$36.91
$17.79B-0.943.86 million shs2.53 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.94
-6.3%
$15.16
$12.47
$22.80
$19.21B0.6210.04 million shs19.07 million shs
Verona Pharma plc stock logo
VRNA
Verona Pharma
$63.36
-4.4%
$63.33
$11.39
$74.18
$5.14B0.21.29 million shs1.94 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%+3.83%+96.82%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
+1.68%-0.08%+48.14%+22.58%+396.98%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
+3.41%+15.95%+33.94%+7.69%+15.21%
Verona Pharma plc stock logo
VRNA
Verona Pharma
-4.17%-8.30%+22.32%+9.96%+345.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.797 of 5 stars
1.10.00.04.50.61.70.6
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
2.8184 of 5 stars
4.51.00.00.03.81.70.0
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.3785 of 5 stars
3.55.00.80.03.80.80.6
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.5712 of 5 stars
4.63.00.00.02.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
3.00
Buy$37.4056.09% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
3.00
Buy$23.7139.99% Upside
Verona Pharma plc stock logo
VRNA
Verona Pharma
3.11
Buy$81.5028.63% Upside

Current Analyst Ratings Breakdown

Latest VRNA, SMMT, TEVA, and ITCI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
5/2/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $41.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.00
4/30/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$75.00 ➝ $85.00
4/28/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
4/28/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
4/28/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.00
4/28/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$100.00
4/25/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$31.00 ➝ $44.00
4/23/2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
$700K25,420.40N/AN/A$0.11 per share217.82
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B1.16$3.35 per share5.05$4.75 per share3.57
Verona Pharma plc stock logo
VRNA
Verona Pharma
$118.54M43.34N/AN/A$3.10 per share20.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.45N/A6.441.44-9.91%42.46%6.65%N/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$54.37M-$2.00N/A2,112.00N/AN/A-79.54%-43.49%N/A

Latest VRNA, SMMT, TEVA, and ITCI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
5/1/2025Q1 2025
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$0.10-$0.09+$0.01-$0.09N/AN/A
4/29/2025Q1 2025
Verona Pharma plc stock logo
VRNA
Verona Pharma
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
2/24/2025Q4 2024
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
-$0.08-$0.08N/A-$0.08N/A$0.20 million
2/21/2025Q4 2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.015.97%N/AN/A N/A
Verona Pharma plc stock logo
VRNA
Verona Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
N/A
8.31
8.31
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75
Verona Pharma plc stock logo
VRNA
Verona Pharma
0.93
13.03
12.88

Institutional Ownership

CompanyInstitutional Ownership
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
4.61%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%
Verona Pharma plc stock logo
VRNA
Verona Pharma
85.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Summit Therapeutics Inc. stock logo
SMMT
Summit Therapeutics
110742.67 million86.28 millionOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable
Verona Pharma plc stock logo
VRNA
Verona Pharma
3081.08 million76.10 millionOptionable

Recent News About These Companies

What Makes Verona Pharma plc (VRNA) a Good Investment?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)
As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$23.96 -0.69 (-2.80%)
As of 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$16.94 -1.13 (-6.25%)
As of 03:59 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Verona Pharma stock logo

Verona Pharma NASDAQ:VRNA

$63.36 -2.90 (-4.38%)
As of 03:59 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.